Bioharmony Therapeutics is Drug Discovery in United States that focus on life-threatening blood business. Founded in 2016. They cover business area such as developer, lysin-base antimicrobial therapeutic, multi-drug resistant Gram-negative infection, second, skin infection, multi-drug resistant acinetobacter baumanii, doctor, hospital-acquire pneumonia, life-threaten blood, wound infection.
2016
( 8 years old in 2024 )
Life-threatening Blood
-
430 East 29th Street
Alexandria LaunchLabs 14th Floor
New York, NY 10016
United States
Private
developerlysin-base antimicrobial therapeuticmulti-drug resistant Gram-negative infectionsecondskin infectionmulti-drug resistant acinetobacter baumaniidoctorhospital-acquire pneumonialife-threaten bloodwound infection
* We use standard office opening hours in near Bioharmony Therapeutics's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
Bioharmony Therapeutics is Drug Discovery business from United States that founded in 2016 (8 years old in 2024), Bioharmony Therapeutics business is focusing on Life-threatening Blood.
Bioharmony Therapeutics headquarter office and corporate office address is located in 430 East 29th Street Alexandria LaunchLabs 14th Floor New York, NY 10016 United States.
Bioharmony Therapeutics was founded in United States.
In 2024, Bioharmony Therapeutics is currently focus on life-threatening blood sector.
Above is snippet of Google Trends for "life-threatening blood" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with Bioharmony Therapeutics, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
